The U.S. Food and Drug Administration has approved the drug risedronate delayed-release to treat osteoporosis in postmenopausal women. The medication comes in tablet form and is only taken once a week, ideally before breakfast. In addition, you need to stay in an upright position for at least 30 minutes after taking it. Commonly reported side effects include joint pain, diarrhea, and stomach pain.
What Is Risedronate Delayed-Release?
Risedronate delayed-release (Atelvia™) is a prescription medication approved for treating osteoporosis in postmenopausal women. It comes in a unique delayed-release tablet that eliminates the need to wait to eat or drink until 30 minutes after taking the tablet, unlike other medications in its class. In fact, risedronate delayed-release is designed to be taken right after breakfast.
Food and Drug Administration, Center for Drug Evaluation and Research. Electronic orange book: approved drug products with therapeutic equivalence evaluations. FDA Web site. Available at: http://www.fda.gov/cder/ob/. Accessed February 22, 2011.
National Library of Medicine (US). Drugs and Lactation Database (LactMED). NLM Web site. Available at: http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT. Accessed February 22, 2011.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click